Diyaliz tipinin kardiyovasküler biyobelirteçler üzerine etkisi

Comparison of the patient subgroups based on the duration of dialysis (36 months) showed that longer dialysis duration was associated with significantly lower values of NT-proBNP, TNF-α, and hs-CRP (p

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objectives: The impact of dialysis type on the biomarkers that reflect the severity of cardiovascular diseases is not clearly known.

📊

Key Findings & Data:Study design: The study included 108 patients who had been on dialysis treatment (57 patients receiving hemodialysis, 51 patients receiving peritoneal dialysis) for ESRD for at least three months.

💡

Conclusion & Impact:Comparison of the patient subgroups based on the duration of dialysis (36 months) showed that longer dialysis duration was associated with significantly lower values of NT-proBNP, TNF-α, and hs-CRP (p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objectives: The impact of dialysis type on the biomarkers that reflect the severity of cardiovascular diseases is not clearly known. We aimed to investigate the effect of dialysis type on biomarkers of cardiovascular diseases in patients with end-stage renal disease (ESRD). Study design: The study included 108 patients who had been on dialysis treatment (57 patients receiving hemodialysis, 51 patients receiving peritoneal dialysis) for ESRD for at least three months. Blood samples were collected just after the dialysis. Serum N-terminal prohormone of brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), cardiac troponin I (TnI), interleukin-6 (IL-6), tumor necrosis factor- alpha (TNF-α), and plasma fibrinogen levels were measured and compared between the two dialysis groups. Results: The two dialysis groups were similar with respect to age and gender. The frequency of hypertension was significantly higher in patients receiving peritoneal dialysis. This group also had higher total cholesterol, HDL cholesterol, LDL cholesterol, and hemoglobin levels. Serum levels of NT-proBNP, hs-CRP, IL-6, and TNF-α, and plasma fibrinogen levels were similar in the two dialysis groups (p>0.05), but TnI was significantly higher in patients receiving peritoneal dialysis (p=0.04). Comparison of the patient subgroups based on the duration of dialysis (36 months) showed that longer dialysis duration was associated with significantly lower values of NT-proBNP, TNF-α, and hs-CRP (p

Özet

Amaç: Diyaliz tipinin kardiyovasküler hastalık ciddiyetini yansıtan biyobelirteçler üzerindeki etkisi tam olarak bilinmemektedir. Bu çalışmada, son dönem böbrek hastalarında diyaliz tipinin kardiyovasküler hastalık belirteçleri üzerindeki etkisi araştırıldı. Çalışma planı: Çalışmaya, son dönem böbrek hastalığı nedeniyle en az üç aydır kronik diyaliz tedavisi görmekte olan 108 hasta alındı. Elli yedi hasta hemodiyaliz tedavisi görürken, 51 hastaya periton diyalizi uygulanıyordu. Kan örnekleri diyalizin hemen sonrasında toplandı. Serumda beyin natriüretik peptidi N-terminal prohormonu (NT-proBNP), yüksek duyarlıklı C-reaktif protein (hs-CRP), kardiyak tropinin I (TnI), interlökin-6 (IL-6), tümör nekroz faktörü-alfa (TNF-α) düzeyleri ve plazma fibrinojen düzeyleri ölçüldü ve iki diyaliz grubu arasında karşılaştırıldı. Bulgular: İki diyaliz grubu yaş ve cinsiyet açısından benzerdi. Periton diyalizi uygulanan hastalarda hipertansiyon sıklığı ve total kolesterol, HDL-kolesterol, LDLkolesterol ve hemoglobin düzeyleri anlamlı derecede daha yüksek idi. Serum NT-proBNP, hs-CRP, IL-6, TNF-α düzeyleri ve plazma fibrinojen düzeyi iki diyaliz grubu arasında anlamlı farklılık göstermedi; serum TnI düzeyi ise periton diyalizi grubunda anlamlı derecede daha yüksek bulundu (p=0.04). Tüm hastalar diyaliz süresine (36 ay) göre gruplandırılarak karşılaştırıldığında, daha uzun diyaliz süresinde NT-proBNP, TNF-α ve hs-CRP düzeyleri anlamlı derecede daha düşük bulundu (p

🔖

Cite This Article

OKYAY, K., DEMİRTAŞ, C., PAŞAOĞLU, H., ŞAHİNARSLAN, A., YALÇIN, R., GÜZ, G., MUTLUAY, R. (2022). Diyaliz tipinin kardiyovasküler biyobelirteçler üzerine etkisi. Türk Kardiyoloji Derneği Arşivi, Cilt: 39 - Sayı: 6, 456–462. https://ajindex.com/articles/633118

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906
Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9
Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334-42
Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999;10:354-65
Roberts MA, Srivastava PM, Macmillan N, Hare DL, Ratnaike S, Sikaris K, et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008;3:1057-65
Gutiérrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 2008;54:1339-48
Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002;80:103-8
Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. Characterization of tumor necrosis factordeficient mice. Proc Natl Acad Sci USA 1997;94:8093-8
Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16
Lucia P, Coppola A, Manetti LL, Sebastiani ML, Colliardo A, Cerroni F, et al. Cardiac troponin I in acute coronary ischemic syndromes. Epidemiological and clinical correlates. Int J Cardiol 2001;77:215-22
Apple FS, Murakami MM, Pearce LA, Herzog CA. Multibiomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50:2279-85
Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospecti